An 18-year-old woman is experiencing hirsutism after a kidney transplant. What is the most appropriate drug adjustment?

In this scenario, the patient is experiencing hirsutism post-kidney transplant, which is a potential side effect of certain immunosuppressive medications. Tacrolimus tends to have a different side effect profile compared to cyclosporine, and one of the known adverse effects of cyclosporine is the potential for hirsutism. By switching from cyclosporine to tacrolimus, the patient may benefit from a reduction in this side effect, since tacrolimus is generally less associated with hirsutism.

Furthermore, tacrolimus is known to provide effective immunosuppression and has better side effects concerning hair growth when compared to cyclosporine. In the context of managing post-transplant patients, this switch can be critical for improving quality of life while still maintaining adequate immunosuppression.

Other options, while potentially addressing aspects of post-transplant care, will not effectively target the specific issue of hirsutism caused by cyclosporine. Therefore, the choice to switch to tacrolimus is the most appropriate drug adjustment in this case.